266 related articles for article (PubMed ID: 33208345)
21. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
Front Immunol; 2019; 10():1527. PubMed ID: 31354708
[No Abstract] [Full Text] [Related]
22. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Shao Q; Wang S; Jiang H; Liu L
Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
[No Abstract] [Full Text] [Related]
24. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.
Seror R; Ravaud P; Bowman SJ; Baron G; Tzioufas A; Theander E; Gottenberg JE; Bootsma H; Mariette X; Vitali C;
Ann Rheum Dis; 2010 Jun; 69(6):1103-9. PubMed ID: 19561361
[TBL] [Abstract][Full Text] [Related]
25. Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.
Iwata N; Tomiita M; Kobayashi I; Inoue Y; Nonaka Y; Okamoto N; Umebayashi H; Hara R; Ito Y; Sato Y; Mori M
Pediatr Rheumatol Online J; 2020 Sep; 18(1):73. PubMed ID: 32943063
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.
He J; Chen J; Miao M; Zhang R; Cheng G; Wang Y; Feng R; Huang B; Luan H; Jia Y; Jin Y; Zhang X; Shao M; Wang Y; Zhang X; Li J; Zhao X; Wang H; Liu T; Xiao X; Zhang X; Su Y; Mu R; Ye H; Li R; Liu X; Liu Y; Li C; Liu H; Hu F; Guo J; Liu W; Zhang WB; Jacob A; Ambrus JL; Ding C; Yu D; Sun X; Li Z
JAMA Netw Open; 2022 Nov; 5(11):e2241451. PubMed ID: 36355371
[TBL] [Abstract][Full Text] [Related]
27. Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome.
Ozek D; Kemer OE; Omma A
Arq Bras Oftalmol; 2019; 82(1):45-50. PubMed ID: 30403265
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.
Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM
Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial.
Norheim KB; Harboe E; Gøransson LG; Omdal R
PLoS One; 2012; 7(1):e30123. PubMed ID: 22253903
[TBL] [Abstract][Full Text] [Related]
30. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
[TBL] [Abstract][Full Text] [Related]
31. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
[TBL] [Abstract][Full Text] [Related]
32. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
Hu W; Qian X; Guo F; Zhang M; Lyu C; Tao J; Gao Z; Zhou Z
Chin Med J (Engl); 2014; 127(15):2721-6. PubMed ID: 25146603
[TBL] [Abstract][Full Text] [Related]
33. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
[TBL] [Abstract][Full Text] [Related]
34. Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'.
Wang B; Chen S; Xuan J; Li Y; Zheng Q; Zhang X; Liu Y; Shi G
Ann Rheum Dis; 2023 Mar; 82(3):e67. PubMed ID: 33504477
[No Abstract] [Full Text] [Related]
35. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome.
de Wolff L; Arends S; Pontarini E; Bombardieri M; Bowman SJ; Bootsma H
Clin Exp Rheumatol; 2021; 39 Suppl 133(6):100-106. PubMed ID: 34796851
[TBL] [Abstract][Full Text] [Related]
36. Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study.
de Frémont GM; Costedoat-Chalumeau N; Lazaro E; Belkhir R; Guettrot-Imbert G; Morel N; Nocturne G; Molto A; Goulenok T; Diot E; Perard L; Ferreira-Maldent N; Le Besnerais M; Limal N; Martis N; Abisror N; Debouverie O; Richez C; Sobanski V; Maurier F; Sauvetre G; Levesque H; Timsit MA; Tieulié N; Orquevaux P; Bienvenu B; Mahevas M; Papo T; Lartigau-Roussin C; Chauvet E; Berthoux E; Sarrot-Reynauld F; Raffray L; Couderc M; Silva NM; Jourde-Chiche N; Belhomme N; Thomas T; Poindron V; Queyrel-Moranne V; Delforge J; Le Ray C; Pannier E; Mariette X; Le Guern V; Seror R;
Lancet Rheumatol; 2023 Jun; 5(6):e330-e340. PubMed ID: 38251600
[TBL] [Abstract][Full Text] [Related]
37. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
[TBL] [Abstract][Full Text] [Related]
38. Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by Wang
Felten R; Gottenberg JE
Ann Rheum Dis; 2023 Mar; 82(3):e68. PubMed ID: 33504476
[No Abstract] [Full Text] [Related]
39. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
[TBL] [Abstract][Full Text] [Related]
40. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]